Asian Pacific Journal of Cancer Prevention

  • 제14권1호
  • /
  • Pages.329-332
  • /
  • 2013
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Somatic Mutations of K-Ras and BRAF in Thai Colorectal Cancer and their Prognostic Value

  • Chaiyapan, Welawee (Tumor Biology Research Unit, Department of Surgery, Faculty of Medicine, Prince of Songkla University) ;
  • Duangpakdee, Pongsanae (Tumor Biology Research Unit, Department of Surgery, Faculty of Medicine, Prince of Songkla University) ;
  • Boonpipattanapong, Teeranut (Tumor Biology Research Unit, Department of Surgery, Faculty of Medicine, Prince of Songkla University) ;
  • Kanngern, Samornmas (Tumor Biology Research Unit, Department of Surgery, Faculty of Medicine, Prince of Songkla University) ;
  • Sangkhathat, Surasak (Tumor Biology Research Unit, Department of Surgery, Faculty of Medicine, Prince of Songkla University)
  • 발행 : 2013.01.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The study aimed to determine the incidence of K-ras and BRAF mutations in colorectal cancers (CRCs) in Thai patients and evaluate association with clinicopathological parameters including treatment outcomes in terms of event free survival (EFS). Materials and Methods: Two-hundred colorectal cancer specimens were collected for studies of K-Ras codon 12, 13 and 61, and BRAF codon 600 by polymerase chain reaction and direct nucleotide sequencing. Results: The overall incidence of K-Ras mutations in our patients was 23%. K-ras mutation frequencies in CRC stages (AJCC) I, II, III and IV were 6.7%, 16.1%, 23.3% and 26.6%, respectively (p-value>0.05). The three most common mutation forms were G12D, G12V and G13D. K-Ras mutation status was associated with poorer EFS in stage I-III CRCs (p-value 0.03). Conclusions: The study found a lower mutation frequency of K-Ras and BRAF compared to reports involving other ethnic groups. However, K-Ras mutations did have a negative prognostic value in early-stage CRCs.

키워드

참고문헌

  1. Bazan V, Agnese V, Corsale S, et al (2005). Specific TP53 and/ or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year gruppo oncologico dell'Italia meridionale (GOIM) prospective study. Ann Oncol, 16, 50-5.
  2. Brink M, de Goeij AF, Weijenberg MP, et al (2003). K-ras oncogene mutations in sporadic colorectal cancer in the Netherlands cohort study. Carcinogenesis, 24, 703-10. https://doi.org/10.1093/carcin/bgg009
  3. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ (2005). The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut, 54, 1283-6. https://doi.org/10.1136/gut.2005.066514
  4. Di Nicolantonio F, Martini M, Molinari F, et al (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 26, 5705-12. https://doi.org/10.1200/JCO.2008.18.0786
  5. Domingo E, Niessen RC, Oliveira C, et al (2005). BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene, 24, 3995-8. https://doi.org/10.1038/sj.onc.1208569
  6. El-Serafi MM, Bahnassy AA, Ali NM, et al (2010). The prognostic value of c-Kit, K-ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer. Cancer, 116, 4954-64. https://doi.org/10.1002/cncr.25417
  7. Font A, Abad A, Monzo M, et al (2001). Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q patients with resected colorectal cancer. Dis Colon Rectum, 44, 549-57. https://doi.org/10.1007/BF02234328
  8. Guerrero S, Casanova I, Farre L, et al (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res, 60, 6750-6.
  9. Jakovljevic K, Malisic E, Cavic M, et al (2012). KRAS and BRAF mutations in Serbian patients with colorectal cancer. J BUON, 17, 575-80.
  10. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  11. Jeon CH, Lee HI, Shin IH, Park JW (2008). Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients. Int J Colorectal Dis, 23, 29-35.
  12. Heideman DA, Lurkin I, Doeleman M, et al (2012). KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn, 14, 247-55. https://doi.org/10.1016/j.jmoldx.2012.01.011
  13. Khukaprema T, Srivatanakul P (2008). Colon and rectum cancer in Thailand: an overview. Jpn J Clin Oncol, 38, 237-43. https://doi.org/10.1093/jjco/hyn020
  14. Kummalue T, Sujiwatanarat P, Wongcharoen P, et al (2011). Mutational analyses of K-ras exon 2 in Thailand colorectal cancer tissue samples. Siriraj Med J, 63, 4-7.
  15. Lamy A, Blanchard F, Le Pessot F, et al (2011). Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol, 24, 1090-100. https://doi.org/10.1038/modpathol.2011.60
  16. Licar A, Cerkovnik P, Novakovic S (2011). Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Med Oncol, 28, 1048-53. https://doi.org/10.1007/s12032-010-9631-z
  17. Mao C, Liao RY, Qiu LX, et al (2011). BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Mol Biol Rep, 38, 2219-23. https://doi.org/10.1007/s11033-010-0351-4
  18. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL (2012). PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and metaanalysis. Ann Oncol, 23, 1518-25. https://doi.org/10.1093/annonc/mdr464
  19. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A (2009). Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract, 205, 858-62 https://doi.org/10.1016/j.prp.2009.07.010
  20. Poehlmann A, Kuester D, Meyer F, et al (2007). K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract, 203, 489-97. https://doi.org/10.1016/j.prp.2007.06.001
  21. Shen H, Yuan Y, Hu HG, et al (2011). Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World J Gastroenterol, 17, 809-16. https://doi.org/10.3748/wjg.v17.i6.809
  22. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009). Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst, 101, 1308-24. https://doi.org/10.1093/jnci/djp280
  23. Sinicrope FA, Sargent DJ (2012). Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res, 18, 1506-12. https://doi.org/10.1158/1078-0432.CCR-11-1469
  24. Sriplung H, Wiangnon S, Sontipong S, Sumitsuwan Y, Martin N (2006). Cancer incidence trends in Thailand, 1989-2000. Asian Pac J Cancer Prev, 7, 239-44
  25. Tan C, Du X (2012). KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol, 18, 5171-80.
  26. Tol J, Nagtegaal ID, Punt CJ (2009). BRAF mutation in metastatic colorectal cancer. N Engl J Med, 361, 98-9. https://doi.org/10.1056/NEJMc0904160
  27. Winder T, Mündlein A, Rhomberg S, et al (2009). Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep, 21, 1283-7.
  28. Wu CM, Tang R, Wang JY, Changchien CR, Hsieh LL (2005). Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan. Cancer Genet Cytogenet, 158, 55-60. https://doi.org/10.1016/j.cancergencyto.2004.08.030
  29. Yen LC, Uen YH, Wu DC, et al (2010). Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg, 251, 254-60. https://doi.org/10.1097/SLA.0b013e3181bc9d96

피인용 문헌

  1. Expression of BMP6 is Associated with its Methylation Status in Colorectal Cancer Tissue but Lacks Prognostic Significance vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7091
  2. BRAF Gene Mutation Analysis in Colorectal Cancer in South of Iran vol.2, pp.2, 2014, https://doi.org/10.17795/acr-19917
  3. mutations in Greek and Romanian patients with colorectal cancer: a cohort study vol.4, pp.5, 2014, https://doi.org/10.1136/bmjopen-2013-004652
  4. High Frequency of Codon 12 but not Codon 13 and 61 K-ras Gene Mutations in Invasive Ductal Carcinoma of Breast in a South Indian Population vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3505
  5. Molecular Biomarkers of Colorectal Cancer: A Review of Published Articles From Iran vol.3, pp.3, 2015, https://doi.org/10.17795/acr-30100
  6. Association of Wilms' tumor 1 gene single-nucleotide polymorphism rs16754 with colorectal cancer vol.3, pp.6, 2015, https://doi.org/10.3892/mco.2015.647
  7. Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.3560
  8. Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine vol.21, pp.2, 2017, https://doi.org/10.1007/s40291-016-0248-6
  9. Clinicopathological Associations of K-RAS and N-RAS Mutations in Indonesian Colorectal Cancer Cohort vol.49, pp.2, 2018, https://doi.org/10.1007/s12029-016-9901-x